Chemomab Therapeutics
CMMB
15 hedge funds and large institutions have $7.14M invested in Chemomab Therapeutics in 2024 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 6 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
193% more capital invested
Capital invested by funds: $2.44M → $7.14M (+$4.7M)
17% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 6
7% more funds holding
Funds holding: 14 → 15 (+1)
0.16% more ownership
Funds ownership: 0.23% → 0.4% (+0.16%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$1.7M |
| 2 |
YLHM
Yelin Lapidot Holdings Management
Tel Aviv,
Israel
|
+$1.14M |
| 3 |
Morgan Stanley
New York
|
+$554K |
| 4 |
TSS
Two Sigma Securities
New York
|
+$56K |
| 5 |
HF
HRT Financial
New York
|
+$19K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$701K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$57.4K |
| 3 |
Two Sigma Investments
New York
|
-$22.3K |
| 4 |
Two Sigma Advisers
New York
|
-$16.5K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
-$10.8K |
CMMB Hedge Fund Activity: Q3 2024 in Review
15 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Chemomab Therapeutics (CMMB) for Q3 2024, worth a combined $7.14M — up 193% from $2.44M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new CMMB positions and 6 closed out — a net gain of 1 holder — while 3 added to existing stakes and 1 trimmed.
The largest buyer was Sphera Funds Management, opening a new position worth an estimated $1.7M. The largest seller was OrbiMed, cutting an estimated $701K.
- 15 institutional investors held Chemomab Therapeutics (CMMB) as of Q3 2024, up from 14 in Q2 2024.
- Funds reported $7.14M of Chemomab Therapeutics stock for Q3 2024, up 193% quarter-over-quarter.
- 7 funds opened new Chemomab Therapeutics positions in Q3 2024 and 6 closed out, a net change of +1 holder.
- The largest Chemomab Therapeutics buyer in Q3 2024 was Sphera Funds Management, an estimated $1.7M added.
- The largest Chemomab Therapeutics seller in Q3 2024 was OrbiMed, an estimated $701K sold.
Based on aggregated 13F filings for Q3 2024.